Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man

Eleanor Barnes, Antonella Folgori, Stefania Capone, Leo Swadling, Stephen Aston, Ayako Kurioka, Joel Meyer, Rachel Huddart, Kira Smith, Rachel Townsend, Anthony Brown, Richard Antrobus, Virginia Ammendola, Mariarosaria Naddeo, Geraldine O'Hara, Chris Willberg, Abby Harrison, Fabiana Grazioli, Maria Luisa Esposito, Loredana SianiCinzia Traboni, Ye Htun Oo, David Adams, Adrian Hill, Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Paul Klenerman

Research output: Contribution to journalArticlepeer-review

301 Citations (Scopus)


Currently, no vaccine exists for hepatitis C virus (HCV), a major pathogen thought to infect 170 million people globally. Many studies suggest that host T cell responses are critical for spontaneous resolution of disease, and preclinical studies have indicated a requirement for T cells in protection against challenge. We aimed to elicit HCV-specific T cells with the potential for protection using a recombinant adenoviral vector strategy in a phase 1 study of healthy human volunteers. Two adenoviral vectors expressing NS proteins from HCV genotype 1B were constructed based on rare serotypes [human adenovirus 6 (Ad6) and chimpanzee adenovirus 3 (ChAd3)]. Both vectors primed T cell responses against HCV proteins; these T cell responses targeted multiple proteins and were capable of recognizing heterologous strains (genotypes 1A and 3A). HCV-specific T cells consisted of both CD4+ and CD8+ T cell subsets; secreted interleukin-2, interferon-γ, and tumor necrosis factor-α; and could be sustained for at least a year after boosting with the heterologous adenoviral vector. Studies using major histocompatibility complex peptide tetramers revealed long-lived central and effector memory pools that retained polyfunctionality and proliferative capacity. These data indicate that an adenoviral vector strategy can induce sustained T cell responses of a magnitude and quality associated with protective immunity and open the way for studies of prophylactic and therapeutic vaccines for HCV.

Original languageEnglish
Pages (from-to)115ra1
JournalScience Translational Medicine
Issue number115
Publication statusPublished - 4 Jan 2012


  • Adenoviridae
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • Cell Proliferation
  • Genotype
  • HEK293 Cells
  • Hepacivirus
  • Hepatitis C
  • Humans
  • Interferon-gamma
  • Interleukin-2
  • Leukocytes, Mononuclear
  • T-Lymphocytes
  • Time Factors
  • Tumor Necrosis Factor-alpha
  • Viral Hepatitis Vaccines


Dive into the research topics of 'Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man'. Together they form a unique fingerprint.

Cite this